JRGE:XETRA:XETRA-JPMorgan ETFs (Ireland) ICAV - Global Research Enhanced Index Equity UCITS ETF EUR Hedged Acc (EUR)

ETF | Others |

Last Closing

USD 41.05

Change

+0.85 (+2.10)%

Market Cap

USD 0.02B

Volume

5.82K

Analyst Target

N/A
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

NA

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2025-04-23 )

Largest Industry Peers for Others

Symbol Name Price(Change) Market Cap
JARI:XETRA Amundi Index Solutions - Amund..

+0.65 (+1.48%)

USD 100.65B
EUNL:XETRA iShares Core MSCI World UCITS ..

N/A

USD 84.07B
FRCJ:XETRA UBS MSCI Japan Socially Respon..

+0.21 (+0.94%)

USD 79.79B
AW15:XETRA UBS (Irl) ETF plc - MSCI Japan..

+0.12 (+0.96%)

USD 58.88B
FJPR:XETRA Fidelity Sustainable Research ..

+0.08 (+1.59%)

USD 44.90B
EXX7:XETRA iShares Nikkei 225 UCITS ETF (..

+0.25 (+1.13%)

USD 28.25B
SPYL:XETRA SPDR S&P 500 UCITS ETF USD Acc..

+0.39 (+3.48%)

USD 23.49B
PPFB:XETRA iShares Physical Gold ETC EUR

-1.90 (-3.28%)

USD 20.66B
XDEE:XETRA Xtrackers S&P 500 Equal Weight..

+0.19 (+2.07%)

USD 12.74B
EUN5:XETRA iShares Core Corporate Bond UC..

+0.02 (+0.01%)

USD 12.26B

ETFs Containing JRGE:XETRA

N/A

Market Performance

  Market Performance vs. Industry/Classification (Others) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -7.00% 40% F 39% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -7.00% 43% F 41% F
Trailing 12 Months  
Capital Gain 4.02% 68% D+ 66% D+
Dividend Return N/A N/A N/A N/A N/A
Total Return 4.02% 69% C- 66% D+
Trailing 5 Years  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Average Annual (5 Year Horizon)  
Capital Gain 10.78% 68% D+ 67% D+
Dividend Return 10.78% 67% D+ 66% D+
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 11.28% 55% F 64% D
Risk Adjusted Return 95.57% 83% B 85% B
Market Capitalization 0.02B 15% F 12% F

Annual Financials (EUR)

Quarterly Financials (EUR)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior risk adjusted returns

This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.

What to not like:
Low market capitalization

This is among the smaller entities in its sectors with below median market capitalization. That may make it less stable in the long run unless it has a unique technology or market which can help it grow or get acquired in future.